



Immunotherapy for Urothelial Carcinoma: Milestones and Future Horizons

Guest Editor:

Dr. Mimma Rizzo

Division of Medical Oncology,
Azienda Ospedaliero
Universitaria Consorziata
Policlinico di Bari, Bari, Italy

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editor

Over the last decade, remarkable advances have been made in the urothelial carcinoma (UC) therapeutic landscape. Nowadays, in addition to the conventional chemotherapeutic approach, we can offer advanced UC patients immune checkpoint inhibitors (ICIs), antibody–drug conjugates (ADCs) and targeted agents (TAs). The UC immunotherapy era, which began with PD-1/PD-L1 inhibitor monotherapy, is currently evolving towards immune combinations with chemotherapy, radiotherapy and targeted agents and ICI adoption in the early disease stages. An increasing number of UC patients will receive immunotherapeutic treatments in the years to come. Therefore, the acquisition of further data from preclinical and clinical models and the detection of prognostic and predictive biomarkers will be crucial to tailoring and optimising the therapeutic strategy for the individual UC patient.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)